Evidence map›Paper›PMID 41200298›Full record

ArticleOpen veterinary journal2025

Global dynamics of vaccine effectiveness and genotype shift in porcine circovirus 2: A cross-temporal analysis.

Fredmoore L Orosco

Abstract read
In one paragraph

Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Fredmoore L OroscoVirology and Vaccine Research Program, Industrial Technology Development Institute, Department of Science and Technology, Taguig, Philippines.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Porcine circovirus type 2 (PCV2) has caused annual economic losses exceeding US$2 billion to the global swine industry, with mortality rates of 5%-20% in unvaccinated herds. Following the 2006 introduction of PCV2a-based vaccines in 2006, genotype dominance shifted sequentially from PCV2a to PCV2b and from 2010 onward to PCV2d. However, a unified, long-term evaluation of how vaccine uptake influences genotype prevalence and viral evolution remains unavailable. Aim: This study aims to quantify the spatio-temporal relationship between vaccine coverage and genotype shifts, compare genotype-specific vaccine-efficacy decay, and identify capsid-protein sites under positive selection in the post-vaccine era. Methods: Annual genotype frequencies (2000-2025) were extracted from OIE surveillance reports, PCV2 cap-gene sequences were retrieved from GenBank, and vaccine-efficacy figures were compiled from peer-reviewed studies. A reproducible pipeline was used to harmonize these streams into three datasets: genotype prevalence, country-level coverage, and time-indexed efficacy. LOESS smoothing and linear mixed-effects models assessed coverage-prevalence associations. The exponential decay parameters (VE-, k) were estimated Results: Vaccine coverage was inversely correlated with PCV2a prevalence ( Conclusion: PCV2 vaccination exerts selective pressure driving genotype succession. The accelerated waning of protection against emergent genotypes and the emergence of escape-associated mutations at key antigenic sites support the development of multivalent vaccines incorporating PCV2d antigens to sustain long-term herd immunity.

Indexed as

Circoviridae InfectionsCircovirusSwine DiseasesVaccine EfficacyViral VaccinesAnimalsGenotypeSpatio-Temporal AnalysisSwineViral VaccinesGenotype shiftMeta-analysisPCV2Vaccine effectivenessViral evolution

Identifiers

PMID41200298
PMCPMC12587875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.